Navigation Links
Study Reaffirms Superiority of Trofile(TM) Assay
Date:12/19/2007

ume operations at commercially reasonable costs; expected reliance on a few customers for the majority of our revenues; the annual renewal of certain customer agreements; actual market acceptance of our products and adoption of our technological approach and products by pharmaceutical and biotechnology companies; our estimate of the size of our markets; our estimates of the levels of demand for our products; the impact of competition; the timing and ultimate size of pharmaceutical company clinical trials; whether payers will authorize reimbursement for our products and services and the amount of such reimbursement that may be allowed; whether the FDA or any other agency will decide to further regulate our products or services, including Trofile; whether the draft guidance on Multivariate Index Assays issued by FDA will be subsequently determined to apply to our current or planned products; whether we will encounter problems or delays in automating our processes; the ultimate validity and enforceability of our patent applications and patents; the possible infringement of the intellectual property of others; whether licenses to third party technology will be available; whether we are able to build brand loyalty and expand revenues; restrictions on the conduct of our business imposed by the Pfizer, Merrill Lynch and other debt agreements; the impact of additional dilution if our convertible debt is converted to equity; and whether we will be able to raise sufficient capital in the future, if required. For a discussion of other factors that may cause actual events to differ from those projected, please refer to our most recent annual report on Form 10-K and quarterly reports on Form 10-Q, as well as other subsequent filings with the Securities and Exchange Commission. We do not undertake, and specifically disclaim any obligation, to revise any forward-looking statements to reflect the occurrence of anticipated or unanticipated events or circumstances after the date of s
'/>"/>
SOURCE Monogram Biosciences, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
3. Kline Study: Better Brushing Habits Boost European Oral Care Sales
4. Evotec to Present Details of the Positive Phase II Study in Insomnia With EVT 201 at the Worldsleep07 Congress in Cairns/Australia
5. NASA study will help stop stowaways to Mars
6. New Study Findings Confirm CLEXANE(R)/LOVENOX(R) Long-Term Clinical Benefit in Patients Suffering From Acute Coronary Syndrome
7. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
8. Evotec Reports Details of the Positive Proof-of-Concept Phase II Study in Insomnia With EVT 201
9. Study Supports Use of GlycoMark Blood Test to Evaluate Therapy in Children with Diabetes
10. Quigley Corporation Releases Update on Quigley Pharmas Phase IIb Clinical Study of QR-333 in Diabetic Peripheral Neuropathy
11. Biodel Inc. Announces VIAject(TM) Phase II Meal Study Data at the 2007 European Association for the Study of Diabetes Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... 2015 Working in collaboration with the ... London , Richmond Pharmacology is the first centre ... study for an investigational RNAi therapeutic being developed for the ... nerves and heart. Read press release ... Based at St Georges University of London ...
(Date:3/26/2015)... WARREN, N.J., March 26, 2015  Roka Bioscience, ... company focused on providing advanced testing solutions for ... financial results for the three months and full ... Quarter 2014 Financial Results:Revenue for the quarter ended ... $689,000 for the fourth quarter of 2013 and ...
(Date:3/26/2015)... DIEGO , March 26, 2015  BioNano Genomics, ... appointment of  Terry Salyer as chief commercial officer. ... highly effective, worldwide sales teams in life sciences. At ... ® System, a genome-mapping platform to assemble a ... investigate structural variations. To date, 32 institutions located in ...
(Date:3/26/2015)... ReliantHeart, Inc., an innovative supplier of advanced ... precision transit-time flow measurement solutions, are collaborating on a ... of the HeartAssist5® Left Ventricular Assist Device ... mobility and peace of mind. , The Transonic ... draw 1/6th of the power required by earlier flow ...
Breaking Biology Technology:Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 2Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 3Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 4Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 5Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 6Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 7BioNano Genomics Appoints Terry Salyer as Chief Commercial Officer 2BioNano Genomics Appoints Terry Salyer as Chief Commercial Officer 3LVAD patients to have greater mobility and peace of mind through Transonic and ReliantHeart’s True Flow collaboration for the HeartAssist5® 2LVAD patients to have greater mobility and peace of mind through Transonic and ReliantHeart’s True Flow collaboration for the HeartAssist5® 3
... Kan., Nov. 16, 2011 The Kansas Bioscience Authority ... ended June 30, and cumulative outcomes since the KBA,s ... investments, are reported annually based on information provided by ... full-time jobs created by bioscience companies in Kansas; ...
... Livestream Info ... http://thehill.com/video/in-the-news/193083-livestreaming-genetic-testing-briefing . , ... is redefining cancer treatment, and the pace of discovery promises ... conditions. That will be among the topics of discussion today ...
... 2011 Nektar Therapeutics (NASDAQ: NKTR ... a next-generation topoisomerase I inhibitor, at the 2011 ... being held in San Francisco, California.  The preclinical ... pegylated liposomal doxorubicin (PLD) in vivo has strong ...
Cached Biology Technology:Kansas Bioscience Authority Announces FY11 Outcomes of $207 Million 2Kansas Bioscience Authority Announces FY11 Outcomes of $207 Million 3Members of Congress, Cancer Experts Address Impact of Genetic Testing on Cancer 2NKTR-102 Demonstrates Synergistic Anti-Tumor Activity in Combination with Pegylated Liposomal Doxorubicin in Platinum-Resistant Ovarian Cancer 2NKTR-102 Demonstrates Synergistic Anti-Tumor Activity in Combination with Pegylated Liposomal Doxorubicin in Platinum-Resistant Ovarian Cancer 3NKTR-102 Demonstrates Synergistic Anti-Tumor Activity in Combination with Pegylated Liposomal Doxorubicin in Platinum-Resistant Ovarian Cancer 4NKTR-102 Demonstrates Synergistic Anti-Tumor Activity in Combination with Pegylated Liposomal Doxorubicin in Platinum-Resistant Ovarian Cancer 5NKTR-102 Demonstrates Synergistic Anti-Tumor Activity in Combination with Pegylated Liposomal Doxorubicin in Platinum-Resistant Ovarian Cancer 6
(Date:3/11/2015)... , March 11, 2015   The ... its platform to scientifically measure and harness music ... to real-time biometrics and objective measurements of physiology, ... music at scale in large populations. It is ... technologists and clinicians perform rigorous studies and accelerate ...
(Date:3/5/2015)... In Brazil , cloud computing ... these solutions and 42 percent planning to invest in them ... percent of the companies will be investing in these solutions ... companies in the region are currently opting for the private ... command significant attention in the coming years. This trend is ...
(Date:3/2/2015)... , March 2, 2015   Neurotechnology , ... today introduced the SentiGaze Software Development Kit ... create applications that use off-the-shelf webcams to track eye ... gazes at a monitor. Heatmaps can be used for ... effectiveness of online advertising. The SDK can also be ...
Breaking Biology News(10 mins):Introducing The Sync Project, a Global Collaboration Harnessing the Scientific Potential of Music for Health 2Introducing The Sync Project, a Global Collaboration Harnessing the Scientific Potential of Music for Health 3Two of Every Three Brazilian Companies will have Invested in Cloud by 2015, Finds Frost & Sullivan 2Two of Every Three Brazilian Companies will have Invested in Cloud by 2015, Finds Frost & Sullivan 3Two of Every Three Brazilian Companies will have Invested in Cloud by 2015, Finds Frost & Sullivan 4Neurotechnology Releases SentiGaze SDK for Eye Movement Tracking Using Ordinary Webcams 2Neurotechnology Releases SentiGaze SDK for Eye Movement Tracking Using Ordinary Webcams 3
... events, two comprehensive, collaborative projects that include the work ... Natural History will grace the covers of the journals ... Science, herpetologist and Associate Dean of Science Christopher Raxworthy ... more typical few keystone species, to determine a conservation ...
... be so old that dinosaurs once lumbered along its rim, ... Colorado at Boulder and the California Institute of Technology. ... show the Grand Canyon may have formed more than 55 ... million to 50 million years. The researchers gathered evidence ...
... the evolutionary history of animals indicates that Earth,s first ... from fossils and studies of living animals--was probably significantly ... which was funded by the National Science Foundation (NSF), ... issue of Nature. Using new high-powered technologies for analyzing ...
Cached Biology News:AMNH scientists grace Science & Nature covers 2AMNH scientists grace Science & Nature covers 3Grand Canyon may be as old as dinosaurs, says new study 2Grand Canyon may be as old as dinosaurs, says new study 3And the first animal on Earth was a... 2And the first animal on Earth was a... 3
Anti-Potassium Channel Kv2.2 Immunogen: Synthetic peptide from rat Kv2.2. Available Date: 38376...
Mouse monoclonal [1241] to Parainfluenza Virus type 2...
Mouse monoclonal [1C6/2] to Rad17 ( Abpromise for all tested applications). entrezGeneID: 5884 SwissProtID: Q9UPF5...
... contain a proprietary high-performance desalting resin, exclusive ... protein-recovery characteristics compared to other commercially available ... g/ml of protein can be processed, providing ... of salts and other small molecules ( ...
Biology Products: